Q1 2016 13F Holders as of 31 Mar 2016
-
Type / Class
-
Debt / NOTE 2.750%12/0
-
Market price (% of par)
-
39.84%
-
Total 13F principal
-
$107,352,000
-
Principal change
-
-$585,000
-
Total reported market value
-
$44,016,000
-
Number of holders
-
15
-
Value change
-
-$323,066
-
Number of buys
-
2
-
Number of sells
-
5
Institutional Holders of OREXIGEN THERAPEUTICS INC - NOTE 2.750%12/0 as of Q1 2016
As of 31 Mar 2016,
OREXIGEN THERAPEUTICS INC - NOTE 2.750%12/0 was held by
15 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$107,352,000
in principal (par value) of the bond.
The largest 10 bondholders included
UBS OCONNOR LLC, SILVERBACK ASSET MANAGEMENT LLC, Partner Fund Management, L.P., FMR LLC, Telemetry Investments, L.L.C., CITADEL ADVISORS LLC, WOLVERINE ASSET MANAGEMENT LLC, ORBIMED ADVISORS LLC, Clearbridge Investments, LLC, and SYMPHONY ASSET MANAGEMENT LLC.
This page lists
15
institutional bondholders reporting positions
for the Q1 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.